Core Viewpoint - Zhonghong Medical's stock price has declined, closing at 14.92 yuan with a drop of 3.24%, indicating a current state of underperformance since its IPO [1] Group 1: IPO and Initial Performance - Zhonghong Medical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1] - The stock reached a peak price of 159.80 yuan on its first trading day, marking the highest price since its listing [1] - Currently, the stock is in a state of decline, having fallen below its initial offering price [1] Group 2: Fundraising and Financials - The total amount raised from the IPO was 2.025 billion yuan, with a net amount of 1.896 billion yuan after expenses, exceeding the originally planned fundraising by 1.317 billion yuan [1] - The initial fundraising plan aimed to raise 580 million yuan for projects related to nitrile gloves and working capital [1] - The total issuance costs for the IPO were 128 million yuan, with underwriting fees accounting for 107 million yuan [1] Group 3: Dividend Distribution - In 2022, Zhonghong Medical announced a profit distribution plan, distributing 7.00 yuan in cash per 10 shares and increasing the total share capital by 9 million shares through capital reserve [2] - For 2021, the company distributed 30.00 yuan in cash per 10 shares and increased the total share capital by 13.33 million shares [2] - The 2024 profit distribution plan includes a cash dividend of 2.5 yuan per 10 shares and a capital reserve increase of 3.88 million shares, resulting in a total share capital of approximately 428.86 million shares [3]

Group 1 - The core viewpoint of the article highlights the decline in the stock price of Duopule (301528.SZ), which closed at 62.51 yuan, reflecting a drop of 3.43% [1] - Duopule was listed on the Shenzhen Stock Exchange's ChiNext board on August 28, 2023, with an issuance of 15.5 million shares at a price of 71.80 yuan per share [1] - On its first trading day, Duopule reached a peak price of 185 yuan, but has since experienced a continuous decline, currently trading below its initial offering price [1] Group 2 - The total amount raised from Duopule's initial public offering (IPO) was 1,112.90 million yuan, with a net amount of 1,007.92 million yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 518.65 million yuan, with the company initially aiming to raise 489.28 million yuan for projects including the construction of a non-destructive testing intelligent production base and a headquarters building and R&D center [1] - The total issuance costs (excluding VAT) amounted to 104.98 million yuan, with underwriting fees accounting for 82.52 million yuan [1]

Group 1 - The core point of the news is that the Vice President of Benli Technology, Sheng Mengjun, plans to reduce his shareholding in the company through a public trading method, which is a normal behavior and will not significantly impact the company's governance structure or control [1] Group 2 - Benli Technology was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on September 14, 2021, with an initial issuance of 17.68 million shares, accounting for 25.01% of the total post-issue share capital, at a price of 42.50 yuan per share [2] - The total funds raised by Benli Technology amounted to 751 million yuan, with a net amount of 683 million yuan after deducting issuance costs, exceeding the original plan by 207 million yuan [2] - The company plans to use the raised funds for various projects, including the expansion of production capacity for specific chemical products and the construction of a research and development center [2] Group 3 - In the 2022 annual profit distribution announcement, Benli Technology declared a cash dividend of 1.5 yuan per 10 shares and a capital reserve increase of 5 shares for every 10 shares held, with the record date set for June 15, 2023 [3]

Core Viewpoint - Shengxiang Biotechnology (688289.SH) announced on December 5 that part of the shares held by its major shareholder, Chen Weny, are subject to judicial freezing and enforcement, which will not affect the company's control or daily operations [1][2]. Group 1: Shareholder and Judicial Actions - The shares subject to judicial freezing include 20,720,000 shares, representing 3.58% of the total share capital, which will be adjusted to a "non-restricted sell freeze" status [2]. - The court will allow the applicant to sell up to 4 million shares through the secondary market at a price not lower than 90% of the average price over the previous 30 trading days, with a deadline for the reduction by June 20, 2026 [2]. Group 2: Company Financials and Stock Performance - Shengxiang Biotechnology raised a total of 201.92 million yuan, with a net amount of 186.93 million yuan, exceeding the original plan by 131.27 million yuan [3]. - The company was listed on the Sci-Tech Innovation Board on August 28, 2020, with an initial issuance of 40 million shares at a price of 50.48 yuan per share, and the stock reached a peak of 155.55 yuan on its first trading day [2]. - Currently, the stock is in a state of decline, having fallen below its initial offering price [2].

中国经济网北京12月8日讯百普赛斯（301080）(301080.SZ)12月5日披露了关于实际控制人之一致行动人及高级管理人员股份减持计划期限届满暨实施结果 的公告。 公司于2025年8月14日披露了《关于实际控制人之一致行动人及高级管理人员减持股份的预披露公告》(公告编号：2025-048)。公司实际控制人陈宜顶的一致 行动人苗景赟计划自2025年9月5日至2025年12月4日以集中竞价或大宗交易方式减持所持有的公司股份合计不超过400,000股(占公司当时总股本的0.24%)。公 司实际控制人陈宜顶的一致行动人安义百普赛斯企业管理咨询合伙企业(有限合伙)(原名为"上海百普赛斯企业管理咨询合伙企业(有限合伙)"，以下简称"安义 百普赛斯")、安义百普嘉乐企业管理咨询合伙企业(有限合伙)(原名为"上海百普嘉乐企业管理咨询合伙企业(有限合伙)"，以下简称"安义百普嘉乐")计划自 2025年9月5日至2025年12月4日以集中竞价或大宗交易方式减持所持有的公司股份合计不超过4,600,000股(占公司当时总股本的2.74%)。公司副总经理、董事 会秘书、财务负责人林涛计划自2025年9月5日至2025年12月4 ...

据宏力达上市发行结果公告显示，宏力达跟投机构为华泰创新投资有限公司，最终战略配售数量为 75.00万股，跟投金额为6617.25万元，占发行总量的3.00%，限售期为24个月。 2023年6月7日，宏力达发布的2022年年度权益分派实施公告显示，本次利润分配及转增股本以方案实施 前的公司总股本1亿股为基数，每股派发现金红利0.96元(含税)，以资本公积金向全体股东每股转增0.4 股。股权登记日为2023年6月12日，除权(息)日为2023年6月13日。 宏力达募集资金总额为22.06亿元，扣除发行费用后，募集资金净额为20.66亿元。宏力达最终募集资金 净额较原计划多8.66亿元。宏力达2020年9月30日发布的招股说明书显示，公司计划募集资金12.00亿 元，分别用于上海生产基地及研发中心和总部大楼建设项目、泉州生产基地建设项目、补充流动资金。 宏力达上市发行费用为1.39亿元，其中保荐机构华泰联合证券有限责任公司获得保荐及承销费用1.24亿 元。 中国经济网北京12月5日讯宏力达(688330.SH)今日收报39.62元，跌幅4.30%，总市值55.47亿元。该股目 前处于破发状态。 宏力达2020年10 ...

Group 1 - The core point of the article is that Aikesaibo (688719.SH) is currently trading at 41.14 yuan, reflecting a decline of 5.64% and is in a state of breaking its initial public offering price [1] - Aikesaibo was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 28, 2023, with an issuance of 20.62 million shares at a price of 69.98 yuan per share [1][2] - On its first trading day, Aikesaibo reached a peak price of 75.39 yuan, which was the highest price since its listing [2] Group 2 - The total funds raised from Aikesaibo's initial public offering amounted to 1.442 billion yuan, with a net amount of 1.318 billion yuan, exceeding the original plan by 937.694 million yuan [2] - The company plans to use the raised funds for several projects, including the industrialization of precision special power supplies and the expansion of precision testing power supply projects [2] - Aikesaibo's total issuance costs were 125.2936 million yuan, with underwriting fees accounting for 106.0091 million yuan [2] Group 3 - Aikesaibo announced a cash dividend of 0.51134 yuan per share and a stock bonus of 0.4 shares per share, with the record date for the dividend on June 20, 2024 [2]

万润新能首次公开发行股票的发行费用为24,295.94万元，其中，保荐及承销费用21,200.00万元。 万润新能于2023年5月24日披露的2022年年度权益分派实施公告显示，本次利润分配及转增股本以方案 实施前的公司总股本85,215,178股为基数，每股派发现金红利3.52元（含税），以资本公积金向全体股 东每股转增0.48股，共计派发现金红利299,957,426.56元，转增40,903,285股，本次分配后总股本为 126,118,463股。本次权益分派股权登记日为2023年5月30日，除权除息日为2023年5月31日。 中国经济网北京11月24日讯 万润新能(688275.SH)今日收报76.47元，跌幅3.18%。该股目前处于破发状 态。 万润新能于2022年9月29日在上交所科创板上市，公开发行2130.3795万股，发行价格299.88元/股，保荐 机构为东海证券股份有限公司，保荐代表人为盛玉照、江成祺。 上市首日，万润新能盘中创下最高价259.99元，为该股上市以来最高价。 万润新能首次公开发行股票募集资金总额638,858.20万元，扣除发行费用后，募集资金净额为614,562.26 ...

Core Viewpoint - Haocen Software (688657.SH) has experienced a significant decline in stock price, closing at 53.36 yuan, down 6.75%, indicating a state of underperformance since its IPO [1] Group 1: IPO Details - Haocen Software was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 10, 2023, with an issuance of 11,218,200 shares at a price of 103.40 yuan per share [1] - The total funds raised from the IPO amounted to 1,159.96 million yuan, with a net amount of 1,050.31 million yuan after deducting issuance costs, exceeding the original plan by 303.25 million yuan [1] - The company planned to use the raised funds for various projects, including CAD cloud platform development, 2D CAD software upgrades, 3D BIM software development, and global marketing and service network construction [1] Group 2: Financials and Future Plans - The total issuance costs for the IPO were 109.65 million yuan, with underwriting and sponsorship fees accounting for 79.81 million yuan [1] - A dividend plan was announced for May 16, 2024, proposing a distribution of 10 yuan (pre-tax) for every 10 shares, along with a bonus issue of 4.6 shares, with the ex-dividend date set for May 23, 2024 [1]

Group 1 - The stock price of YN Technology (688348.SH) fell by 8.15% to 54.10 yuan, currently in a state of breaking issue [1] - YN Technology was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 8, 2022, with an initial offering price of 163.00 yuan per share and issued 20 million shares [1] - The total amount raised from the initial public offering (IPO) was 326 million yuan, with a net amount of 303.7 million yuan, exceeding the original plan by 2.481 billion yuan [1] Group 2 - The company announced a cash dividend of 2.2 yuan per share and a capital reserve increase of 0.4 shares for every share held, totaling 176 million yuan in cash dividends and 32 million shares in capital increase [2] - The total share capital after the distribution will be 112 million shares, with the record date on June 20, 2023, and the ex-dividend date on June 21, 2023 [2] - For the 2024 dividend plan, the company will distribute 10 yuan for every 10 shares and increase 4 shares for every 10 shares held, with the record date on July 2, 2024, and the ex-dividend date on July 3, 2024 [2]